argenx SE (ARGX)
NASDAQ: ARGX
· Real-Time Price · USD
734.39
-5.64 (-0.76%)
At close: Sep 23, 2025, 3:59 PM
-0.76% (1D)
| Bid | 733.29 |
| Market Cap | 44.92B |
| Revenue (ttm) | 3.66B |
| Net Income (ttm) | 1.37B |
| EPS (ttm) | 19.67 |
| PE Ratio (ttm) | 37.34 |
| Forward PE | 30.74 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 775 |
| Volume | 240,817 |
| Avg. Volume (20D) | 426,519 |
| Open | 736.17 |
| Previous Close | 740.03 |
| Day's Range | 733.11 - 742.07 |
| 52-Week Range | 510.06 - 779.03 |
| Beta | 0.00 |
| Ex-Dividend Date | n/a |
About ARGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecastsargenx SE is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+4.54%
Argenx shares are trading higher after Piper Sandl...
Unlock content with
Pro Subscription
1 month ago
+2.62%
Argenx shares are trading higher after the company reported its Phase 3 ADAPT SERON study met its primary endpoint. Additionally, RBC Capital initiated coverage on the stock with an Outperform rating and announced a price target of $850.
1 month ago · seekingalpha.com
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic ShiftsInsmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...